Drug recall · November 8, 2023
Liothyronine Sodium Tablets recall
Why: Failed Impurities/Degradation Specifications.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Liothyronine Sodium Tablets, USP, 5 mcg, 100-count bottles, Rx only, Distributed by: Sun Pharmaceutical Industries, Inc.Cranbury, NJ 08512, Manufactured by: Sun Pharmaceutical Industries Ltd. Survey No. 259/15, Dadra-396 191,(U.T. of D & NH), India. NDC 62756-589-88
- Lots / codes
Lot #: DND0058A, Exp. Date 12/2023
- Quantity
- 7392 Bottles
- Company
- Sun Pharmaceutical Industries Inc, Princeton, NJ
- Distribution
- Nationwide within the United States
- Initiated
- October 20, 2023 · Voluntary: Firm initiated
- Classified
- November 1, 2023
- Reported
- November 8, 2023
- Ended
- July 25, 2024
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Liothyronine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.